FDA approval of Zurzuvae (zuranolone) to combat postpartum depression

Dear Editor,

The escalating burden of mental illnesses over recent decades has ignited a pressing concern that demands our unwavering attention. It is well known that a woman’s body goes through several physical, physiological, and psychological changes during pregnancy. ¹ Postpartum Depression (PPD) is marked by a diverse range of changes in behavior, physical well-being, and emotions, all of which take place within the initial month following childbirth. This condition not only impacts maternal welfare significantly but also has the potential to disrupt parenting behavior, ultimately affecting the optimal growth and development of the child.^1,2

The majority of individuals with PPD typically experience recovery within a few months, although around 25-30% may still grapple with PPD a year following childbirth. ³ Suicide contributes to about 20% of postpartum fatalities, with 5-14% of pregnant and postpartum women reporting thoughts of suicide. ⁴

Alterations in physiological pathways that occur during pregnancy and in the postpartum period have been linked to disruptions in brain serotonin synthesis, offering potential avenues for targeted interventions. ¹ Neurosteroids, as important modulators of neuronal stress, could offer insight into establishing homeostasis and supporting maternal mental health during this critical period. ⁵

On August 4, 2023, a groundbreaking approval by the U.S. Food and Drug Administration marked a pivotal moment in maternal mental health care - the approval of Zurzuvae (zuranolone), the first oral neuroactive steroid and GABAA receptor-positive allosteric modulator medication indicated to treat postpartum depression in adults. ⁶ This approval underscores the pressing need for effective interventions to combat the complex web of physiological, psychological, and emotional changes that women experience during pregnancy and childbirth.

Zuranolone is an orally administered investigational medication with synthetic properties. It acts as a positive allosteric modulator (PAM) on both synaptic and extrasynaptic GABAA receptors, promoting the upregulation of GABAA receptor expression and augmenting inhibitory GABAergic signaling. This enhancement results in the rapid reduction of anxiety levels and alleviation of symptoms associated with depression. It's important to note that dysfunction or damage to the transmembrane channels comprising GABAA receptors can contribute to the development of anxiety and neurodevelopmental disorders. Zuranolone has therapeutic potential in such cases, as it can help restore the proper functioning of dysfunctional GABAA receptors, leading to the relief of depression symptoms. ⁷ But Zuranolone, differs from benzodiazepines in its mode of action. Zuranolone operates by enhancing the activity of the GABA-A receptor through an increase in the receptor’s sensitivity to its natural neurotransmitter, gamma-aminobutyric acid (GABA). In contrast, benzodiazepines directly activate the GABA-A receptor, inducing its opening and facilitating the flow of chloride ions into neurons, ultimately resulting in an inhibitory effect on neuronal activity. Furthermore, it is worth noting that zuranolone may exhibit a reduced potential for the development of dependence and tolerance as it does not directly initiate receptor activation, potentially mitigating the extent of receptor desensitization that can occur with prolonged use. Additionally, Zuranolone might have a more rapid onset of action compared to traditional antidepressants, that often require several weeks of continuous use before their full therapeutic effects are realized.^8,9

Beyond pharmacological interventions like Zurzuvae, several factors play pivotal roles in influencing the onset and course of PPD. Exercise during pregnancy, for instance, has shown to have a significant albeit small effect on postpartum depressive symptoms. The Mediterranean diet (MD), characterized by its rich composition of nutrients, has emerged as a dietary pattern with ample evidence supporting its positive impact on depression in adults. ¹⁰ Addressing malnutrition and deficiencies in key nutrients such as B and D vitamins, n-3 polyunsaturated fatty acids, trace minerals, folate, iron, and antioxidants through targeted interventions could further contribute to reducing the risk of PPD occurrence. ¹⁰ The rampant use of opioid prescription drugs following cesarean and vaginal deliveries for pain management, combined with the high prevalence of mental health conditions among pregnant women, raises concerns about potential adverse outcomes. ³ Studies have indicated that opioid use increases the risk of postpartum depression, necessitating a judicious approach to pain management that takes into account both physical and mental well-being. ³

Thus, the recent approval of Zurzuvae is a ray of hope, backed by robust clinical trials demonstrating its efficacy in alleviating depressive symptoms. Two randomized, double-blind, placebo-controlled multicenter studies revealed that patients receiving Zurzuvae exhibited substantial improvements in depressive symptoms, a significant breakthrough in the field of maternal mental health treatment. ⁶ The primary endpoint of both studies was the change in depressive symptoms using the total score from the 17-item Hamilton depression rating scale (HAMD-17), measured on day 15. Patients in the Zurzuvae groups showed significantly more improvement in their symptoms compared to those in the placebo groups. ⁶ Zuranolone binds to a specific site on the GABAA receptor, distinct from the GABA binding site, and enhances the receptor’s response to GABA. This effect is believed to contribute to its therapeutic action in treating conditions like postpartum depression (PPD), where disruptions in neurotransmitter balance and neural activity are thought to play a role in the development of depressive symptoms. ¹¹ Therefore, Further research into the intricate interplay of hormonal, neuroimmune, and inflammatory factors during pregnancy and the postpartum period is essential.

The predominant adverse events observed in the group receiving zuranolone included somnolence, headache, dizziness, upper respiratory tract infection, diarrhea, and sedation. The use of Zurzuvae has been associated with the potential for inducing suicidal ideation and behavior in individuals. ⁶ Furthermore, animal studies conducted on rats have indicated that the drug may pose a risk of causing harm to fetal development when administered during pregnancy. ⁶ Therefore, careful consideration and monitoring are essential when utilizing Zurzuvae, especially in individuals who may be at risk for these adverse effects, and it should be avoided during pregnancy due to the potential for harm to the developing fetus.

In conclusion, the FDA’s approval of Zurzuvae marks a significant advancement in addressing postpartum depression, illuminating the intricate challenges faced by new mothers. Although this medication has exhibited promising outcomes in clinical trials, the potential for adverse effects, such as suicidal thoughts and fetal harm during pregnancy, underscores the need for thorough assessment and vigilant monitoring when contemplating its usage. Nonetheless, it is crucial to adopt a comprehensive strategy that encompasses elements like physical activity, dietary considerations, pain management, and further exploration of underlying physiological mechanisms. Effective management and treatment of postpartum depression are essential, not only for the well-being of mothers but also for the healthy development of their offspring.